Sorafenib (Ligesitai) 200mg*60's | Jiangxi Shanxiang China Generic | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

分享
Product description

Generic Information: Ligesitai (China)

Ligesitai (利格司他) is a domestic Chinese generic of sorafenib manufactured by Jiangxi Shanxiang Pharmaceutical Co., Ltd. Each tablet delivers 200 mg of sorafenib tosylate, with 60 tablets per box. The product has passed China's generic-quality consistency evaluation, making it therapeutically equivalent to the originator Nexavar while being considerably more affordable.

What Is Ligesitai Used For?

Ligesitai is indicated for unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and radioactive-iodine-refractory differentiated thyroid carcinoma. It serves as a first-line oral targeted therapy for advanced liver cancer and a standard option for advanced kidney cancer.

How Does Sorafenib (Ligesitai) Work?

Ligesitai works by inhibiting CRAF/BRAF and the receptor tyrosine kinases VEGFR-2/3, PDGFR-beta, c-Kit and FLT3. This multi-target action suppresses tumour-cell proliferation and blocks the formation of tumour-feeding blood vessels, thereby slowing disease progression.

Indications

The approved indications are unresectable HCC, advanced RCC, and radioiodine-refractory DTC. Treatment should be supervised by an oncology specialist with regular follow-up.

Dosage

The standard dose is 400 mg twice daily (800 mg per day), taken at least one hour before or two hours after food. One 60-tablet box lasts roughly 15 days at this dose. Stepwise dose reductions are applied when side effects occur.

Side Effects

Common side effects include hand-foot skin reaction, diarrhoea, fatigue, rash, hypertension, nausea and hair thinning. Serious but rare effects are liver toxicity, bleeding, cardiac events and gastrointestinal perforation. Blood pressure, liver function and blood counts should be checked regularly.

Storage

Keep the tablets at room temperature in a dry, dark place, in the original packaging, out of reach of children, and discard after the expiry date.

Why Choose the GLT?

Ligesitai offers sorafenib at a domestic-China price point that is far below Western list prices for the originator. For patients and institutions who need to continue therapy over many months, this consistency-evaluated generic dramatically reduces the cost of care while preserving the efficacy of the original molecule.

How to Order

To order Ligesitai, message GLT on WhatsApp at +86 15234153837 or email [email protected]. We confirm availability, price and shipping from our Hong Kong-licensed facility before you commit.

FAQ

Who makes Ligesitai? Ligesitai is made by Jiangxi Shanxiang Pharmaceutical Co., Ltd., a Chinese pharmaceutical manufacturer.

Is Ligesitai a generic of Nexavar? Yes, it is a generic containing the same sorafenib active ingredient, approved for the same indications.

What is the price advantage? As a domestic generic, Ligesitai is substantially cheaper than originator sorafenib, easing the long-term cost of treatment.

Related Oncology Products

康曲欣 KangQuXin(阿伐曲泊帕)20mg×10片 | 北京康蒂尼(Gyre)| GLT

康曲欣 KangQuXin — 阿伐曲泊帕,北京康蒂尼药业(Gyre Therapeutics,纳斯达克:GYRE)出品,中国大陆

Olumiant(巴瑞替尼)2mg/4mg 片 | JAK1/JAK2 抑制剂 | 礼来(美国)| GLT

礼来公司的选择性 JAK1/JAK2 抑制剂,用于类风湿关节炎、特应性皮炎和重度斑秃。

Barinat(巴瑞替尼)4mg | 仿制 JAK1/JAK2 抑制剂 | Natco Pharma Limited | GLT

由 Natco Pharma Limited(印度)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

SPINRAZA(诺西那生钠)12mg/5mL | 中国购买 | SMA 疗法 | GLT

渤健首创的反义寡核苷酸 SMA 疗法,已获 NMPA 批准并纳入中国国家医保——从 GLT 购买,价格仅为欧美的一小部分。

欣可平 XinKePing(阿伐曲泊帕)20mg*10片 | 南京恒生制药 | GLT

欣可平——南京恒生制药(济民可信集团)马来酸阿伐曲泊帕片,原料药与制剂一体化生产,中国大陆

AVATODX(阿伐曲泊帕)20mg*30片 | 大熊制药(老挝)| GLT

AVATODX——Bigbear Pharmaceutical (Lao) Co., Ltd. 生产的阿伐曲泊帕 20mg,老挝注册号 06L0985/23,30 片瓶装。

Tixepa(替尔泊肽)20mg/2mL 和 30mg/2mL 多剂量注射笔 | Drug International | GLT

Tixepa——Drug International Limited (DIL) 替尔泊肽多剂量注射笔,两种官方规格(Tixepa-5=20mg/2mL,Tixepa-7.5=30mg/2mL)用于 2 型糖尿病和肥胖。